S 32730

Drug Profile

S 32730

Latest Information Update: 20 Sep 1999

Price : $50

At a glance

  • Originator Kaken Pharmaceutical
  • Class Antibacterials; Quinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 20 Sep 1999 S 32730 is available for licensing (http://www.kaken.co.jp/)
  • 04 Aug 1998 No-Development-Reported for Bacterial infections in Japan (Unknown route)
  • 03 Sep 1996 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top